GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lionco Pharmaceutical Group Co Ltd (SHSE:603669) » Definitions » Current Deferred Revenue

Lionco Pharmaceutical Group Co (SHSE:603669) Current Deferred Revenue : ¥0.0 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Lionco Pharmaceutical Group Co Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Lionco Pharmaceutical Group Co's current deferred revenue for the quarter that ended in Mar. 2025 was ¥0.0 Mil.

Lionco Pharmaceutical Group Co Current Deferred Revenue Historical Data

The historical data trend for Lionco Pharmaceutical Group Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lionco Pharmaceutical Group Co Current Deferred Revenue Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lionco Pharmaceutical Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lionco Pharmaceutical Group Co Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Lionco Pharmaceutical Group Co's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lionco Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
Executives
Zhang Jun Ke Director
Wang Wen Nan Director
Tao Xiao Gang Director
Tao Ling Gang Director
Tao Ling Ping Director

Lionco Pharmaceutical Group Co Headlines

No Headlines